Relevance of Urine Telomerase in the Diagnosis of Bladder Cancer

Maria Aurora Sanchini, MSc
Roberta Gunelli, MD
Oriana Nanni, MSc
Sara Bravaccini, BSic
Carla Fabbri, MSc
Alice Sermasi, BSic
Eduard Bercovich, MD
Alberto Ravaiol, MD
Dino Amadori, MD
Daniele Calistri, PhD

THE INCIDENCE OF HUMAN BLADDER cancer has greatly increased over the last few decades, with more than 60,000 new cases diagnosed each year in the United States alone, and now represents the 4th most common malignancy in men and the 10th most common in women. According to the latest reports from the National Cancer Institute, the incidence of this pathology is higher in industrialized than in developing countries.

Bladder cancer is 3 times more common among men than women, and the incidence increases with age. Approximately 80% of newly diagnosed individuals are aged 60 years or older. At present, about 20% of patients die each year, but when the disease is diagnosed and treated in the early stage, the chances of survival are good, thus highlighting the importance of a timely and accurate diagnosis.

More than 90% of newly diagnosed bladder cancers are transitional-cell carcinomas. Approximately 75% of patients present with superficial cancer, 20% with invasive disease, and the remaining 5% with metastatic disease at first diagnosis.

Established approaches for detecting bladder cancer include urine cytology and cystoscopy, used singly or in sequence. However, the invasiveness and relatively high cost of cystoscopic examination and the limited sensitivity of urinalysis, especially for low-grade superficial lesions, make it of the utmost importance to develop a noninvasive, reliable, and simple test to increase the rate of detection of bladder cancer. Among the markers investigated for this purpose, an important role has been played by telomerase activity in voided urine or bladder washings, determined by telomerase activity levels to accurately detect the presence of bladder tumors in men. This test represents a potentially useful noninvasive diagnostic innovation for bladder cancer detection in high-risk groups such as habitual smokers or in symptomatic patients.

JAMA. 2005;294:2052-2056

©2005 American Medical Association. All rights reserved.
primer-telomeric repeats generated in the telomerase reaction.\textsuperscript{12,13} Using this assay, telomerase activity has been detected in almost all superficial urothelial cell carcinomas, but not in healthy urothelia.\textsuperscript{16} We used the TRAP assay with the internal standard developed by Wright et al\textsuperscript{17} and added a reference curve to obtain more accurate and reproducible results.\textsuperscript{18}

The promising results from our pilot study\textsuperscript{18} prompted us to carry out a case-control study, prospectively planned and performed blindly on urine from male individuals to validate the 50 arbitrary enzymatic units (AEUs) that emerged as the best cutoff and to define the diagnostic accuracy of different telomerase activity cutoff values in terms of sensitivity and specificity.

**METHODS**

**Case Series**

The study was conducted in 218 men (FIGURE 1), of whom 84 were healthy individuals and 134 were patients at first diagnosis of bladder cancer, frequency matched by age (\[\leq 75\) years and \(> 75\) years). Median age was 62.4 years (range, 22-98 years) in healthy individuals and 69.8 years (range, 33-88 years) in patients.

Healthy individuals were recruited from hospital laboratory staff and geriatric wards, and none had been previously clinically diagnosed with any type of cancer or with inflammatory pathologies of the urogenital tract.

Patients were prospectively enrolled from the Urology Departments of Pierantoni-Morgagni Hospital (Forlì) and Infermi Hospital (Rimini) between March 2003 and November 2004. All patients underwent cystoscopy as a reference standard for bladder cancer detection, and all tumors or suspicious lesions were resected. Patients who had undergone previous treatment were excluded.

The final diagnosis of bladder cancer was based on histologic examination. Histologic type and tumor cell differentiation were determined according to World Health Organization criteria. Fifteen (11%) tumors were well differentiated (G1), 55 (41%) were moderately differentiated (G2), and 57 (42%) were poorly differentiated (G3). There was 1 carcinoma in situ. Grading was not available for 6 patients.

Demographic data and medical history were collected at study entry. The local ethics committee reviewed and approved the study protocol for each center, and all participants provided written informed consent.

**Urine Collection**

Urine samples from both healthy individuals and patients were processed for cytological diagnosis and TRAP assay.

Each patient evaluated for bladder cancer provided a voided urine sample immediately before cystoscopy.

**Cytology**

Cytological examination was performed in all the urine samples from healthy individuals (n=84) and in 103 of the 134 bladder cancer patients analyzed with TRAP assay. Forty-eight (46.6%) patients had positive cytology, 40 (38.8%) had negative cytology, 8 (7.8%) patients with suspicious cytology findings had evidence of bladder cancer at histologic examination, and 7 (6.8%) had nonassessable cytology because of a lack of exfoliated cells. The cytological examination was unavailable for 31 patients because they bypassed this preliminary urine evaluation and directly underwent cystoscopy.

**TRAP Assay**

Cell extract preparation and TRAP assay were carried out as previously described.\textsuperscript{18,19} Cells were pelleted by centrifugation (850g for 10 minutes at 4°C) within 1 to 3 hours of urine sample collection, washed once in phosphate-buffered saline, resedimented by centrifugation (2300x for 5 minutes at 4°C), and stored at \(-80\)°C until use (a maximum of 12 months). The pelleted cells were resuspended in 200 µL of lysis reagent\textsuperscript{18} and left on ice for 30 minutes.

---

**Figure 1. Study Flow Diagram**

<table>
<thead>
<tr>
<th>TRAP Assay Results</th>
<th>Cytology Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive TRAP</td>
<td>Positive Cytology</td>
</tr>
<tr>
<td>Negative TRAP</td>
<td>Negative Cytology</td>
</tr>
<tr>
<td>Inconclusive</td>
<td>Inconclusive</td>
</tr>
</tbody>
</table>

TRAP indicates telomeric repeat amplification protocol. The target condition in this study was bladder cancer.

©2005 American Medical Association. All rights reserved.
Cell lysates were centrifuged (10,000g for 20 minutes at 4°C), and the supernatant extracts were stored at −80°C. Aliquots of each urine sample containing 1 µg of protein lysate were used for the TRAP assay. Telomerase products were evaluated on fluorescence electropherograms, and the area underlying the different peaks was calculated. To obtain semiquantitative levels of telomerase activity, an internal telomerase assay standard (ITAS; 25 attograms17), amplified by the same 2 primers used for the telomerase assay, was included in the TRAP buffer. Protein concentrations corresponding to 10, 30, 100, 300, 1000, and 3000 cells of a human bladder cancer line (MCR)18 were analyzed in each assay and used as the reference curve. To obtain quantitative evaluations of telomerase activity, the areas of each sample were also normalized to the 150-base pair ITAS peak. The relative telomerase activity per cell for each sample is presented as the percentage of the ratio of TRAP ladder/ITAS per cell vs the value of MCR and expressed in AEUs. All experiments were performed in duplicate, and when variations were greater than 15%, observed in about 10% of cases, a third analysis was performed. Telomerase activity was expressed as a continuous variable in all analyses.

Statistical Analysis

The population size was defined on the basis of results from the previous pilot study18, in which we obtained 93% sensitivity and 90% specificity using the 50-AEU cutoff value for the subgroup of male individuals. In fact, for the 84 healthy individuals and 134 bladder cancer patients of the present study, we predicted the 95% confidence interval (CI) to be ±5% with respect to the single estimated value for sensitivity and specificity. To avoid bias in the clinical utility of the TRAP assay, we analyzed all samples prospectively, without previous knowledge of the patient’s clinico-pathologic status.

The threshold value for optimal sensitivity and specificity was determined using a receiver operating characteristic (ROC) curve,20 constructed by calculating the true-positive (sensitivity) and false-positive (1–specificity) rates at several cutoff values. Sensitivity, specificity, and relative 95% CIs were calculated for the most discriminant cutoff values. The relationship between urine telomerase activity and histological grading was analyzed using the median test. For all tests, a 2-sided P=.05 was regarded as significant. Data analyses were performed with SAS release 8.0 (SAS Institute Inc, Cary, NC).

All statistical analyses were performed at the Unit of Biostatistics and Clinical Trials of Istituto Oncologico Romagnolo, Forlì, Italy.

RESULTS

The median telomerase activity value in urine was 27 AEUs (range, 0–88) in healthy individuals and 112 AEUs (range, 30–382) in patients. We did not observe any patients with a telomerase activity value lower than 30 AEUs or any healthy individuals with a telomerase activity value higher than 90 AEUs. Moreover, in patients with negative or positive cytology, the median telomerase activity values in urine were 99 (range, 38–265) and 134 (range, 37–253) AEUs, respectively.

As primary end point, we validated the results obtained in the pilot study using a 50-AEU cutoff value. In the overall series, 90% (95% CI, 83%–94%) sensitivity and 88% (95% CI, 79%–93%) specificity were observed.

As secondary end point, the diagnostic relevance of urine telomerase activity was analyzed for the overall series and for the subgroups of individuals 75 years or younger and older than 75 years. The ROC curve analysis provides a graphic demonstration of the sensitivity and specificity of telomerase activity in the overall series and the even higher specificity in the subgroup of individuals 75 years or younger (Figure 2).

In particular, sensitivity in the overall series ranged from 61% to 100% and specificity from 54% to 100% according to the different AEU cutoff values (Table 1). As shown in Figure 2, a similar sensitivity and an even higher specificity (94%) (95% CI, 85%–98%) was obtained in the subgroup of individuals 75 years or younger.

Although an increase in urine telomerase activity levels was observed from histologic grades 1 to 3, it did not reach statistical significance (Table 2).

The sensitivity of urine telomerase activity in detecting bladder tumors was similar in the subgroups of patients with different tumor grades at all AEU cutoff values. In particular, at 50 AEUs the sensitivity was 93%, 87%, and 89% for grades 1, 2, and 3, respectively (Table 3).

COMMENT

Telomerase has been investigated as a potentially useful biomarker for early cancer detection8,21-23 and prognosis24 and for monitoring residual disease.21 Elevated levels of telomerase expression, in particular of the human telomerase reverse transcriptase catalytic subunit, have been observed in almost all human tumor histotypes, including bladder cancer. In contrast, telomerase...
ase activity has not been detected in most of the somatic cells. 25-30

We confirmed the high sensitivity and specificity of urine telomerase levels, in particular of the 50-AEU cutoff observed in our pilot study, in detecting bladder cancer. 18

Moreover, we observed that sensitivity is not age dependent, whereas specificity is higher in individuals younger than 75 years.

The test we developed requires a small amount of urine; is noninvasive, inexpensive, and easy to perform; and permits a quantitative evaluation of telomerase activity in urine. Furthermore, it is objective, reproducible, and specific and is not reliant on the expertise of the cytopathologist. 9 Another important advantage of this test is its ability to also identify low-grade tumors, which often escape detection during cytopathologic examination.

However, notwithstanding the validated optimal diagnostic accuracy of the test, it is not recommended for use in routine screening programs because of the low incidence of bladder cancer, and should be aimed at high-risk subgroups. Specifically, smokers have about a 3-fold increased risk of developing bladder cancer compared with nonsmokers. It might be even more advantageous in terms of cost/benefit to use the TRAP assay in selected individuals who present with hematuria. For this subgroup, the incidence of bladder cancer is about 10% to 15% and the sensitivity of urinary cytology is only 30% to 50%. 31-33 Although cystoscopy is the gold standard for the diagnosis of bladder cancer because of its 90% sensitivity, the invasiveness and low specificity of the procedure in 90% sensitivity, the invasiveness and low specificity of the procedure in 50% of patients, median (range) 88 (38-382) 100 (30-265) 122 (35-344)

Abbreviations: AEU, arbitrary enzymatic unit; CI, confidence interval.

Table 1. Sensitivity and Specificity of Urine Telomerase Activity in the Overall Series and in Individuals Aged ≤75 Years

<table>
<thead>
<tr>
<th>Cutoff, AEU</th>
<th>Overall Series (N = 218)</th>
<th>≤75 y (n = 157)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity</td>
<td>Specificity</td>
</tr>
<tr>
<td>30</td>
<td>100 (54-64)</td>
<td>100 (45-71)</td>
</tr>
<tr>
<td>40</td>
<td>96 (91-98)</td>
<td>73 (62-81)</td>
</tr>
<tr>
<td>50</td>
<td>90 (83-94)</td>
<td>88 (79-93)</td>
</tr>
<tr>
<td>60</td>
<td>76 (68-83)</td>
<td>90 (82-95)</td>
</tr>
<tr>
<td>70</td>
<td>69 (61-76)</td>
<td>95 (88-98)</td>
</tr>
<tr>
<td>80</td>
<td>63 (54-70)</td>
<td>98 (92-99)</td>
</tr>
<tr>
<td>90</td>
<td>61 (53-69)</td>
<td>100</td>
</tr>
</tbody>
</table>

Abbreviations: AEU, arbitrary enzymatic unit; CI, confidence interval.

Table 2. Relationship Between Telomerase Activity and Histologic Grade*

<table>
<thead>
<tr>
<th>Cutoff, AEUs</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, No.</td>
<td>15</td>
<td>55</td>
<td>57</td>
</tr>
<tr>
<td>AEUs, median (range)</td>
<td>88 (38-382)</td>
<td>100 (30-265)</td>
<td>122 (35-344)</td>
</tr>
</tbody>
</table>

Abbreviation: AEUs, arbitrary enzymatic units.

*Median test, \( \chi^2 = 0.76, P = .68 \).

Table 3. Sensitivity of Urine Telomerase Activity in Patients With Different Tumor Grades

<table>
<thead>
<tr>
<th>Cutoff, AEU</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>40</td>
<td>93 (70-99)</td>
<td>96 (88-99)</td>
<td>95 (86-98)</td>
</tr>
<tr>
<td>50</td>
<td>93 (70-99)</td>
<td>87 (76-94)</td>
<td>89 (79-95)</td>
</tr>
<tr>
<td>60</td>
<td>73 (48-89)</td>
<td>71 (58-81)</td>
<td>79 (67-88)</td>
</tr>
<tr>
<td>70</td>
<td>60 (36-90)</td>
<td>65 (52-77)</td>
<td>75 (63-85)</td>
</tr>
<tr>
<td>80</td>
<td>53 (30-75)</td>
<td>60 (47-72)</td>
<td>68 (56-79)</td>
</tr>
<tr>
<td>90</td>
<td>47 (25-70)</td>
<td>54 (45-70)</td>
<td>68 (56-79)</td>
</tr>
</tbody>
</table>

Abbreviations: AEU, arbitrary enzymatic units; CI, confidence interval.

In conclusion, we believe that our telomerase activity urine assay, with the reliability verified in pilot and confirmatory studies, represents a promising and potentially important contribution to the early diagnosis of bladder carcinoma, in particular for high-risk subgroups. Further prospective studies on larger patient populations are needed to assess the diagnostic role of urine telomerase, to define the ability of this assay to detect low-grade tumors, and to forecast clinical relapse.

Author Contributions: Ms Sanchini had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Sanchini, Nanni.

Acquisition of data: Sanchini, Gunelli, Fabbri, Sermasi, Bercovich, Ravaoli, Amadori, Calistri.

Analysis and interpretation of data: Sanchini, Bravaccini, Calistri.

Drafting of the manuscript: Sanchini, Gunelli, Bercovich, Ravaoli, Calistri.

Critical revision of the manuscript for important intellectual content: Sanchini, Nanni, Bravaccini, Fabbri, Sermasi, Amadori, Calistri.

Statistical analysis: Sanchini, Nanni.

Obtained funding: Sanchini, Amadori, Calistri.

©2005 American Medical Association. All rights reserved.
URINE TELOMERASE IN THE DIAGNOSIS OF BLADDER CANCER

Administrative, technical, or material support: Sanchini, Gunelli, Bravaccini, Fabbrini, Sermasi, Bercovich, Ravaoli, Amadori, Calistri.

Study supervision: Sanchini, Calistri.

Financial Disclosures: None reported.

Funding/Support: This work was supported by Istituto Oncologico Romagnolo, Forlì and the National Research Council (Consiglio Nazionale delle Ricerche [National Research Council]—Ministero dell’Istruzione, dell’Università e della Ricerca [Ministry of Education, University and Research] “Oncologia”; grants 02.00082.ST97 and 03.00073.ST97).

Role of the Sponsors: Istituto Oncologico Romagnolo and the National Research Council supplied the funding but did not participate in the design and conduct of the study; in the collection, management, analysis, and interpretation of the results; or in the preparation, review, or approval of the manuscript.

Independent Statistical Analysis: Independent statistical analysis was performed by Oriana Nanni, MSc, at the Unit of Biostatistics and Clinical Trials of Istituto Oncologico Romagnolo, Forlì, Italy.

Acknowledgment: We thank Rosella Silvestrini, PhD, Istituto Oncologico Romagnolo, for her invaluable scientific contribution and Gráinne Tierney, BSc, Division of Oncology and Diagnostics, Morgagni-Pierantoni Hospital, Forlì, for editing the manuscript. We also thank Giuliana Amadori, RN, of the Department of Geniatrics, Morgagni-Pierantoni Hospital, for assistance in sample collection. None of those acknowledged received compensation from the study sponsors.

REFERENCES


©2005 American Medical Association. All rights reserved.

Downloaded From: https://jama.jamanetwork.com/ by a Non-Human Traffic (NHT) User on 08/18/2019